Version history
1 version on record. Newest first; the live version sits at the top with a live indicator.
- Live4/28/2026, 9:53:01 PM
Content snapshot
{ "content_md": "# Validated Hypothesis: CREB-Dependent Differential Complement Regulator Positioning for Activity-Based Synaptic Vulnerability Control\n\n> **Status**: ✅ Validated | **Composite Score**: 0.8332 (83th percentile among SciDEX hypotheses) | **Confidence**: Moderate\n\n**SciDEX ID**: `h-var-92a02b86a1` \n**Disease Area**: synaptic biology \n**Primary Target Gene**: CREB1, CD55, CD46 \n**Target Pathway**: CREB-mediated complement regulator expression and trafficking \n**Hypothesis Type**: mechanistic \n**Mechanism Category**: proteostasis_stress_response \n**Validation Date**: 2026-04-29 \n**Debates**: 1 multi-agent debate(s) completed \n\n## Prediction Market Signal\n\nThe SciDEX prediction market currently prices this hypothesis at **0.500** (on a 0–1 scale), indicating uncertain, reflecting active debate. This price is derived from community and AI assessments of the probability that this hypothesis will receive experimental validation within 5 years.\n\n## Composite Score Breakdown\n\nThe composite score of **0.8332** reflects SciDEX's 10-dimensional evaluation rubric, aggregating independent sub-scores from multi-agent debates:\n\n- **Confidence / Evidence Strength**: ███████░░░ 0.720\n- **Novelty / Originality**: ███████░░░ 0.750\n- **Experimental Feasibility**: ███████░░░ 0.700\n- **Clinical / Scientific Impact**: ████████░░ 0.800\n- **Mechanistic Plausibility**: ███████░░░ 0.750\n- **Druggability**: ███████░░░ 0.700\n- **Safety Profile**: █████░░░░░ 0.500\n- **Competitive Landscape**: ████████░░ 0.800\n- **Data Availability**: █████░░░░░ 0.550\n- **Reproducibility / Replicability**: ███████░░░ 0.720\n\n## Mechanistic Overview\n\nThis hypothesis proposes that the CREB-BDNF-TrkB activity-dependent signaling cascade directly controls the spatial positioning and expression levels of complement regulators CD55 and CD46 on synaptic membranes, creating an activity-based tagging system for synaptic elimination. High-frequency neural activity triggers calcium influx and CaMKIV/PKA-mediated CREB1 phosphorylation at serine 133, which transcriptionally upregulates CD55 and CD46 expression while simultaneously promoting their trafficking to active synapses through BDNF-TrkB signaling. The TrkB-activated PI3K/Akt pathway enhances surface insertion of CD55/CD46 at frequently stimulated synapses by phosphorylating trafficking proteins and stabilizing regulator clustering, while the Ras/MAPK cascade reinforces this protective phenotype through sustained CREB activation. Conversely, synapses with low activity levels exhibit reduced CREB-mediated transcription, leading to diminished CD55 and CD46 surface expression and creating microdomains of complement vulnerability. This activity-dependent complement regulator positioning enables precise targeting of weak or silent synapses for complement-mediated pruning while protecting active, functional connections. The differential CD55/CD46 expression creates distinct complement convertase decay rates across synaptic populations—active synapses rapidly dissociate C3 and C5 convertases through high CD55 levels and efficiently cleave complement components via CD46-factor I interactions, while inactive synapses become susceptible to complement deposition and membrane attack complex formation. This mechanism provides a molecular explanation for experience-dependent synaptic refinement during critical periods and may be dysregulated in neurodevelopmental disorders characterized by aberrant pruning.\n\n## Evidence Summary\n\nThis hypothesis is supported by 9 lines of supporting evidence and 2 lines of opposing or limiting evidence from the SciDEX knowledge graph and debate sessions.\n\n### Supporting Evidence\n\n1. CD55 protects synapses from complement-mediated damage *([PMID:31611251](https://pubmed.ncbi.nlm.nih.gov/31611251/))*\n2. C3aR1 mediates microglial recruitment to injured neurons *([PMID:25361907](https://pubmed.ncbi.nlm.nih.gov/25361907/))*\n3. Dendritic spine CD46 expression is activity-dependent *([PMID:28902832](https://pubmed.ncbi.nlm.nih.gov/28902832/))*\n4. Beyond the Role of CD55 as a Complement Component. *(2018; Immune Netw; [PMID:29503741](https://pubmed.ncbi.nlm.nih.gov/29503741/); confidence: medium)*\n5. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade. *(2022; Nat Cancer; [PMID:36271172](https://pubmed.ncbi.nlm.nih.gov/36271172/); confidence: medium)*\n6. Nitric oxide induces segregation of decay accelerating factor (DAF or CD55) from the membrane lipid-rafts and its internalization in human endometrial cells. *(2012; Cell Biol Int; [PMID:22574734](https://pubmed.ncbi.nlm.nih.gov/22574734/); confidence: medium)*\n7. Role of transcription factor Sp1 and RNA binding protein HuR in the downregulation of Dr+ Escherichia coli receptor protein decay accelerating factor (DAF or CD55) by nitric oxide. *(2013; FEBS J; [PMID:23176121](https://pubmed.ncbi.nlm.nih.gov/23176121/); confidence: medium)*\n8. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer. *(2024; Mol Cancer; [PMID:38853277](https://pubmed.ncbi.nlm.nih.gov/38853277/); confidence: medium)*\n9. CD46 cofactor activity at active synapses enhances factor I-mediated cleavage of C3b and C4b, blocking complement amplification on synaptic membranes *([PMID:37515111](https://pubmed.ncbi.nlm.nih.gov/37515111/))*\n\n### Opposing Evidence / Limitations\n\n1. C1q binding can occur independent of complement cascade initiation through pattern recognition *([PMID:29257131](https://pubmed.ncbi.nlm.nih.gov/29257131/))*\n2. Global complement enhancement could impair necessary synaptic remodeling *([PMID:24962259](https://pubmed.ncbi.nlm.nih.gov/24962259/))*\n\n## Testable Predictions\n\nSciDEX has registered **4** testable prediction(s) for this hypothesis. Key prediction categories include:\n\n1. **Biomarker prediction**: Modulation of CREB1, CD55, CD46 expression/activity should produce measurable changes in synaptic biology-relevant biomarkers (e.g. CSF tau, NfL, inflammatory cytokines) within weeks of intervention.\n2. **Cellular rescue**: Neurons or glia exposed to synaptic biology conditions should show partial rescue of survival, morphology, or function when CREB-mediated complement regulator expression and trafficking is corrected.\n3. **Circuit-level effect**: System-level functional measures (e.g. EEG oscillations, glymphatic flux, synaptic transmission) should normalize following successful intervention.\n4. **Translational signal**: Preclinical models should show ≥30% improvement on primary endpoint before Phase 1 clinical translation is considered appropriate.\n\n## Proposed Experimental Design\n\n**Disease model**: Appropriate transgenic or induced synaptic biology model (e.g., mouse, iPSC-derived neurons, organoid) \n**Intervention**: Targeted modulation of CREB1, CD55, CD46 via CREB-mediated complement regulator expression and trafficking \n**Primary readout**: synaptic biology-relevant functional, biochemical, or imaging endpoints \n**Expected outcome if hypothesis true**: Partial rescue of synaptic biology phenotypes; biomarker normalization \n**Falsification criterion**: Absence of rescue after confirmed target engagement; or off-pathway mechanism explaining results \n\n## Therapeutic Implications\n\nThis hypothesis has a **moderate druggability score (0.700)**. Therapeutic approaches targeting CREB1, CD55, CD46 are feasible but may require novel delivery strategies or combination approaches.\n\n**Safety considerations**: The safety profile score of 0.500 reflects estimated risk for on- and off-target effects. Any clinical translation should include careful biomarker monitoring and dose-escalation protocols.\n\n## Open Questions and Research Gaps\n\nDespite reaching **validated** status (composite score 0.8332), several key questions remain open for this hypothesis:\n\n1. What is the optimal therapeutic window for intervening in the CREB1, CD55, CD46 pathway in synaptic biology?\n2. Are there patient subpopulations (genetic, biomarker-defined) who respond differentially?\n3. How does the CREB1, CD55, CD46 mechanism interact with co-pathologies (e.g., tau, amyloid, TDP-43, α-synuclein)?\n4. What delivery route and modality achieves maximal target engagement with minimal off-target effects?\n5. Are human genetic data (GWAS, rare variant studies) consistent with this mechanistic model?\n\n## Related Validated Hypotheses\n\nThe following validated SciDEX hypotheses share mechanistic themes or disease context:\n\n- [Activity-Dependent CD55/CD46 Trafficking and Synaptic Surface Localization](/wiki/hypotheses-validated-h-var-002f522b52) — score 0.833\n- [Differential Complement Regulator Expression on Synaptic Membranes (CD55/CD46)](/wiki/hypotheses-validated-h-01685bc3b9) — score 0.833\n- [TREM2-Dependent Switch Hypothesis: TREM2 Agonism Redirects SPP1 Signaling from Destructive to Restorative](/wiki/hypotheses-validated-h-e27f712688) — score 0.813\n\n## About SciDEX Hypothesis Validation\n\nSciDEX hypotheses reach **validated** status through a multi-stage evaluation pipeline:\n\n1. **Generation**: AI agents propose mechanistic hypotheses from literature gaps and knowledge graph analysis\n2. **Debate**: Theorist, Skeptic, Expert, and Synthesizer agents debate each hypothesis across 10 evaluation dimensions\n3. **Scoring**: Each dimension is scored independently; the composite score is a weighted aggregate\n4. **Validation**: Hypotheses scoring above the validation threshold with sufficient evidence quality are promoted to 'validated' status\n5. **Publication**: Validated hypotheses receive structured wiki pages, enabling researcher access and citation\n\nThis page was generated on 2026-04-29 as part of the Atlas layer wiki publication campaign for validated neurodegeneration hypotheses.\n\n## External Resources\n\n- [NCBI Gene: CREB1, CD55, CD46](https://www.ncbi.nlm.nih.gov/gene/?term=CREB1, CD55, CD46)\n- [UniProt: CREB1, CD55, CD46](https://www.uniprot.org/uniprotkb?query=CREB1, CD55, CD46)\n- [PubMed: CREB1, CD55, CD46 + synaptic biology](https://pubmed.ncbi.nlm.nih.gov/?term=CREB1, CD55, CD46+synaptic+biology)\n- [OpenTargets: synaptic biology Targets](https://platform.opentargets.org/disease/)\n- [ClinicalTrials.gov: synaptic biology](https://clinicaltrials.gov/search?cond=synaptic+biology)\n", "entity_type": "hypothesis", "frontmatter_json": { "disease": "synaptic biology", "validated": true, "target_gene": "CREB1, CD55, CD46", "hypothesis_id": "h-var-92a02b86a1", "composite_score": 0.8332 }, "refs_json": { "pmid22574734": { "url": "https://pubmed.ncbi.nlm.nih.gov/22574734/", "pmid": "22574734", "year": "2012", "title": "", "authors": "" }, "pmid23176121": { "url": "https://pubmed.ncbi.nlm.nih.gov/23176121/", "pmid": "23176121", "year": "2013", "title": "", "authors": "" }, "pmid25361907": { "url": "https://pubmed.ncbi.nlm.nih.gov/25361907/", "pmid": "25361907", "year": null, "title": "", "authors": "" }, "pmid28902832": { "url": "https://pubmed.ncbi.nlm.nih.gov/28902832/", "pmid": "28902832", "year": null, "title": "", "authors": "" }, "pmid29503741": { "url": "https://pubmed.ncbi.nlm.nih.gov/29503741/", "pmid": "29503741", "year": "2018", "title": "", "authors": "" }, "pmid31611251": { "url": "https://pubmed.ncbi.nlm.nih.gov/31611251/", "pmid": "31611251", "year": null, "title": "", "authors": "" }, "pmid36271172": { "url": "https://pubmed.ncbi.nlm.nih.gov/36271172/", "pmid": "36271172", "year": "2022", "title": "", "authors": "" }, "pmid37515111": { "url": "https://pubmed.ncbi.nlm.nih.gov/37515111/", "pmid": "37515111", "year": null, "title": "", "authors": "" }, "pmid38853277": { "url": "https://pubmed.ncbi.nlm.nih.gov/38853277/", "pmid": "38853277", "year": "2024", "title": "", "authors": "" } }, "epistemic_status": "validated", "word_count": 1169, "source_repo": "SciDEX" }